2023 Q3 Form 10-Q Financial Statement

#000175789823000010 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.342B $1.285B
YoY Change 11.82% 11.07%
Cost Of Revenue $748.8M $711.1M
YoY Change 12.07% 11.33%
Gross Profit $593.5M $573.5M
YoY Change 11.5% 10.75%
Gross Profit Margin 44.22% 44.64%
Selling, General & Admin $380.7M $359.1M
YoY Change 17.78% 7.3%
% of Gross Profit 64.13% 62.61%
Research & Development $27.04M $25.50M
YoY Change 8.49% 3.03%
% of Gross Profit 4.56% 4.45%
Depreciation & Amortization $152.3M $137.9M
YoY Change 13.76% -0.68%
% of Gross Profit 25.66% 24.05%
Operating Expenses $407.7M $384.6M
YoY Change -51.4% 7.0%
Operating Profit $185.9M $188.9M
YoY Change -160.66% 19.26%
Interest Expense $36.94M $32.36M
YoY Change 41.41% 42.72%
% of Operating Profit 19.88% 17.13%
Other Income/Expense, Net -$35.70M -$30.97M
YoY Change 33.99% 32.09%
Pretax Income $150.2M $157.9M
YoY Change -145.08% 17.02%
Income Tax $33.81M $34.12M
% Of Pretax Income 22.52% 21.61%
Net Earnings $115.3M $123.6M
YoY Change -136.58% 11.05%
Net Earnings / Revenue 8.59% 9.62%
Basic Earnings Per Share $1.17 $1.25
Diluted Earnings Per Share $1.16 $1.25
COMMON SHARES
Basic Shares Outstanding 98.78M shares 98.65M shares
Diluted Shares Outstanding 99.41M shares 99.24M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $214.0M $208.6M
YoY Change -17.14% -34.05%
Cash & Equivalents $213.8M $208.6M
Short-Term Investments
Other Short-Term Assets $199.0M $166.1M
YoY Change -2.92% 12.63%
Inventory $821.1M $768.8M
Prepaid Expenses
Receivables $940.3M $887.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.174B $2.031B
YoY Change 15.13% 9.92%
LONG-TERM ASSETS
Property, Plant & Equipment $1.744B $1.921B
YoY Change 10.9% 22.12%
Goodwill $4.040B $3.887B
YoY Change 9.04% -10.06%
Intangibles $3.058B $2.865B
YoY Change -0.64% -10.27%
Long-Term Investments
YoY Change
Other Assets $72.63M $80.04M
YoY Change 0.55% 14.08%
Total Long-Term Assets $9.107B $8.753B
YoY Change 5.87% -6.28%
TOTAL ASSETS
Total Short-Term Assets $2.174B $2.031B
Total Long-Term Assets $9.107B $8.753B
Total Assets $11.28B $10.78B
YoY Change 7.54% -3.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $293.6M $260.7M
YoY Change 25.85% 13.84%
Accrued Expenses $306.7M $332.8M
YoY Change 0.86% 4.76%
Deferred Revenue
YoY Change
Short-Term Debt $70.94M $63.44M
YoY Change -53.02% -57.99%
Long-Term Debt Due $71.00M $63.44M
YoY Change -52.98% -57.99%
Total Short-Term Liabilities $873.1M $886.9M
YoY Change 0.03% -2.36%
LONG-TERM LIABILITIES
Long-Term Debt $3.366B $2.860B
YoY Change 17.13% 0.48%
Other Long-Term Liabilities $76.55M $859.0M
YoY Change 0.85% 1075.48%
Total Long-Term Liabilities $3.443B $3.719B
YoY Change 16.71% 27.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $873.1M $886.9M
Total Long-Term Liabilities $3.443B $3.719B
Total Liabilities $5.091B $4.606B
YoY Change 8.88% -3.42%
SHAREHOLDERS EQUITY
Retained Earnings $2.046B $1.981B
YoY Change 20.7% -3.71%
Common Stock $4.519B $4.498B
YoY Change -3.96% -5.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.178B $6.178B
YoY Change
Total Liabilities & Shareholders Equity $11.28B $10.78B
YoY Change 7.54% -3.61%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $115.3M $123.6M
YoY Change -136.58% 11.05%
Depreciation, Depletion And Amortization $152.3M $137.9M
YoY Change 13.76% -0.68%
Cash From Operating Activities $146.1M $281.1M
YoY Change 40.72% 21.31%
INVESTING ACTIVITIES
Capital Expenditures $83.30M $66.60M
YoY Change -200.64% -42.55%
Acquisitions $0.00
YoY Change
Other Investing Activities -$522.9M $5.000K
YoY Change 3349.89% -99.92%
Cash From Investing Activities -$606.2M -$66.60M
YoY Change 519.05% -39.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 470.2M -213.6M
YoY Change -1146.1% 51.07%
NET CHANGE
Cash From Operating Activities 146.1M 281.1M
Cash From Investing Activities -606.2M -66.60M
Cash From Financing Activities 470.2M -213.6M
Net Change In Cash 10.10M 896.0K
YoY Change -125.86% -102.8%
FREE CASH FLOW
Cash From Operating Activities $146.1M $281.1M
Capital Expenditures $83.30M $66.60M
Free Cash Flow $62.80M $214.5M
YoY Change -66.34% 85.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
-17000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
-6000 usd
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.43
CY2023Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.47
CY2023Q2 us-gaap Revenues
Revenues
1284542000 usd
CY2022Q2 us-gaap Revenues
Revenues
1156491000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
711081000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
638693000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
573461000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
517798000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
359058000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
334626000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25502000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24751000 usd
CY2023Q2 us-gaap Restructuring Costs
RestructuringCosts
19000 usd
CY2022Q2 us-gaap Restructuring Costs
RestructuringCosts
26000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
384579000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
359403000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
188882000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
158395000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
32361000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
22674000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1393000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-770000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30968000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23444000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
157914000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
134951000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34124000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24196000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
123790000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
110755000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
236000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-507000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
123554000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
111262000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.11
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.10
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.47
CY2022Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.43
CY2022Q2 us-gaap Profit Loss
ProfitLoss
110755000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-507000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
111262000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
-17000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
-6000 usd
CY2023Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
58000 usd
CY2022Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
29000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
9793000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-178594000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9851000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-178565000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
133405000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67303000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
123790000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
137925000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
138863000 usd
CY2023Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-445000 usd
CY2022Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5304000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
11579000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
8963000 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-93000 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
972000 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-3878000 usd
CY2023Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1995000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
110755000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-178565000 usd
CY2022Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-10412000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42446000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-26335000 usd
CY2023Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
67956000 usd
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
58076000 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14355000 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6755000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-20572000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6492000 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
37919000 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-26963000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
281129000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
231746000 usd
CY2023Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66601000 usd
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115933000 usd
CY2023Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000 usd
CY2022Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1288000 usd
CY2023Q2 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 usd
CY2022Q2 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
5228000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66596000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-109417000 usd
CY2023Q2 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
15000000 usd
CY2022Q2 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
111875000 usd
CY2023Q2 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-144651000 usd
CY2022Q2 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
37011000 usd
CY2023Q2 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
89000 usd
CY2022Q2 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
84000 usd
CY2023Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8724000 usd
CY2022Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
24679000 usd
CY2023Q2 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
46427000 usd
CY2022Q2 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
43008000 usd
CY2023Q2 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
1254000 usd
CY2022Q2 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
1221000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-213637000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-141414000 usd
CY2023Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-639000 usd
CY2022Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-12908000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
257000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31993000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
208357000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348320000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
208614000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
316327000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6087172000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9851000 usd
CY2023Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8724000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12834000 usd
CY2023Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.47
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
46427000 usd
CY2023Q2 ste Increase Decrease In Noncontrolling Interests Other
IncreaseDecreaseInNoncontrollingInterestsOther
-124000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6544637000 usd
CY2022Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
24679000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
10182000 usd
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.43
CY2022Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
43008000 usd
CY2022Q2 ste Increase Decrease In Noncontrolling Interests Other
IncreaseDecreaseInNoncontrollingInterestsOther
-194000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6419128000 usd
CY2023Q2 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2023 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2024.</span></div>
CY2023Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
46118000 usd
CY2022Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
57528000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1649862000 usd
CY2023Q2 ste Asset Acquisition Tax Deductible Goodwill Expected
AssetAcquisitionTaxDeductibleGoodwillExpected
60000000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
267300000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
239081000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
117589000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
97756000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
433185000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
404238000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
49239000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
45582000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
768835000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
695493000 usd
CY2023Q2 us-gaap Land
Land
84170000 usd
CY2023Q1 us-gaap Land
Land
84313000 usd
CY2023Q2 ste Delayed Draw Term Loan Long Term Portion
DelayedDrawTermLoanLongTermPortion
585000000 usd
CY2023Q1 ste Delayed Draw Term Loan Long Term Portion
DelayedDrawTermLoanLongTermPortion
593125000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
2860116000 usd
CY2023Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
728597000 usd
CY2023Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
691933000 usd
CY2023Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1028237000 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
994188000 usd
CY2023Q2 ste Capitalized Computer Hardware Software Gross
CapitalizedComputerHardwareSoftwareGross
255127000 usd
CY2023Q1 ste Capitalized Computer Hardware Software Gross
CapitalizedComputerHardwareSoftwareGross
247873000 usd
CY2023Q2 us-gaap Materials Supplies And Other
MaterialsSuppliesAndOther
641381000 usd
CY2023Q1 us-gaap Materials Supplies And Other
MaterialsSuppliesAndOther
637920000 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
464408000 usd
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
478316000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3201920000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3134543000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1475829000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1429031000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1726091000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1705512000 usd
CY2023Q2 ste Term Loan Current Portion
TermLoanCurrentPortion
30938000 usd
CY2023Q1 ste Term Loan Current Portion
TermLoanCurrentPortion
27500000 usd
CY2023Q2 ste Delayed Draw Term Loan Current Portion
DelayedDrawTermLoanCurrentPortion
32500000 usd
CY2023Q1 ste Delayed Draw Term Loan Current Portion
DelayedDrawTermLoanCurrentPortion
32500000 usd
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
63438000 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
60000000 usd
CY2023Q2 us-gaap Line Of Credit
LineOfCredit
158164000 usd
CY2023Q1 us-gaap Line Of Credit
LineOfCredit
301672000 usd
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
20241000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
21444000 usd
CY2023Q2 ste Term Loan Long Term Portion
TermLoanLongTermPortion
34688000 usd
CY2023Q1 ste Term Loan Long Term Portion
TermLoanLongTermPortion
45000000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
3018655000 usd
CY2023Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
2923554000 usd
CY2023Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
3078655000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
68706000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
48565000 usd
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
16079000 usd
CY2023Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
11080000 usd
CY2023Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
26727000 usd
CY2023Q1 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
33605000 usd
CY2023Q2 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
17418000 usd
CY2023Q1 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
29257000 usd
CY2023Q2 us-gaap Other Postretirement Benefits Payable Current And Noncurrent
OtherPostretirementBenefitsPayableCurrentAndNoncurrent
1121000 usd
CY2023Q1 us-gaap Other Postretirement Benefits Payable Current And Noncurrent
OtherPostretirementBenefitsPayableCurrentAndNoncurrent
1121000 usd
CY2023Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
2061000 usd
CY2023Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
2014000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
132112000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
125642000 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
91661000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
92283000 usd
CY2023Q2 ste Serviceliabilities
Serviceliabilities
75095000 usd
CY2023Q1 ste Serviceliabilities
Serviceliabilities
72033000 usd
CY2023Q2 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
11704000 usd
CY2023Q1 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
11325000 usd
CY2023Q2 us-gaap Accrued Sales Commission Current And Noncurrent
AccruedSalesCommissionCurrentAndNoncurrent
34003000 usd
CY2023Q1 us-gaap Accrued Sales Commission Current And Noncurrent
AccruedSalesCommissionCurrentAndNoncurrent
31096000 usd
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
13845000 usd
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
13683000 usd
CY2023Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
516000 usd
CY2023Q1 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
543000 usd
CY2023Q2 ste Accrued Interest
AccruedInterest
18109000 usd
CY2023Q1 ste Accrued Interest
AccruedInterest
9243000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
87827000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
87611000 usd
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
332760000 usd
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
317817000 usd
CY2023Q2 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
22171000 usd
CY2023Q1 us-gaap Self Insurance Reserve Noncurrent
SelfInsuranceReserveNoncurrent
22171000 usd
CY2023Q2 us-gaap Other Postretirement Benefits Payable Noncurrent
OtherPostretirementBenefitsPayableNoncurrent
5952000 usd
CY2023Q1 us-gaap Other Postretirement Benefits Payable Noncurrent
OtherPostretirementBenefitsPayableNoncurrent
6070000 usd
CY2023Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2978000 usd
CY2023Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2876000 usd
CY2023Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1129000 usd
CY2023Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1153000 usd
CY2023Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
10097000 usd
CY2023Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
10082000 usd
CY2023Q2 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
21469000 usd
CY2023Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
12588000 usd
CY2023Q2 ste Longtermliabilitiesother
Longtermliabilitiesother
12808000 usd
CY2023Q1 ste Longtermliabilitiesother
Longtermliabilitiesother
21197000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
76604000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
76137000 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.216
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.179
CY2023Q2 us-gaap Income Tax Examination Estimate Of Possible Loss
IncomeTaxExaminationEstimateOfPossibleLoss
12000000 usd
CY2023Q2 ste Income Tax Examination Amount Of Loss Paid
IncomeTaxExaminationAmountOfLossPaid
7500000 usd
CY2023Q2 ste Uncertain Tax Liability Resulting From Irs Notice
UncertainTaxLiabilityResultingFromIRSNotice
50000000 usd
CY2023Q2 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2023, which was filed with the SEC on May 26, 2023, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.</span></div>
CY2023Q2 ste Amortizationandimpairmentofacquiredintangibleassets
Amortizationandimpairmentofacquiredintangibleassets
93925000 usd
CY2022Q2 ste Amortizationandimpairmentofacquiredintangibleassets
Amortizationandimpairmentofacquiredintangibleassets
93929000 usd
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2709000 usd
CY2022Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
9832000 usd
CY2023Q2 ste Redomiciliaton And Tax Restructuring Costs Ax Restructuring
RedomiciliatonAndTaxRestructuringCostsAxRestructuring
9000 usd
CY2022Q2 ste Redomiciliaton And Tax Restructuring Costs Ax Restructuring
RedomiciliatonAndTaxRestructuringCostsAxRestructuring
173000 usd
CY2023Q2 ste Lossgainonfairvaluecontingentconsiderationadjustments
Lossgainonfairvaluecontingentconsiderationadjustments
0 usd
CY2022Q2 ste Lossgainonfairvaluecontingentconsiderationadjustments
Lossgainonfairvaluecontingentconsiderationadjustments
-3100000 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-3878000 usd
CY2023Q2 ste Amortizationofinventoryandpropertystepuptofairvalue
Amortizationofinventoryandpropertystepuptofairvalue
1843000 usd
CY2022Q2 ste Amortizationofinventoryandpropertystepuptofairvalue
Amortizationofinventoryandpropertystepuptofairvalue
1637000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
19000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
26000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
188882000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
158395000 usd
CY2023Q2 us-gaap Revenues
Revenues
1284542000 usd
CY2022Q2 us-gaap Revenues
Revenues
1156491000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98708000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100082000 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
531000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
640000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99239000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100722000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 ste Deferred Ordinary Shares
DeferredOrdinaryShares
25000 shares
CY2023Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
68177 shares
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
14283000 usd
CY2023Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
51494 shares
CY2023Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8724000 usd
CY2022Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
57704 shares
CY2022Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
11737000 usd
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2386686 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0357
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0241
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0108
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0080
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.2798
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.2445
CY2023Q2 ste Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0222
CY2022Q2 ste Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0254
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1749729 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
154.60
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
241456 shares
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
219.97
CY2023Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
31342 shares
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
57.18
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2128 shares
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
200.46
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1957715 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
164.17
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
124831000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1336601 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
136.78
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
119338000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
601967 shares
CY2023Q2 ste Common Stock Fair Market Value Per Share
CommonStockFairMarketValuePerShare
224.98
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4831000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3897000 usd
CY2023Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1254000 usd
CY2022Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1221000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
53.45
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
50.04
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
99504000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
13683000 usd
CY2023Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
3796000 usd
CY2023Q2 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
3634000 usd
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
13845000 usd
CY2023Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
73000 usd
CY2022Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-936000 usd
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
15678000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
16199000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-320710000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10211000 usd
CY2023Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-360000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9851000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-310859000 usd
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-209808000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-178440000 usd
CY2022Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-125000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-178565000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-388373000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001757898-23-000010-index-headers.html Edgar Link pending
0001757898-23-000010-index.html Edgar Link pending
0001757898-23-000010.txt Edgar Link pending
0001757898-23-000010-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ste-20230630.htm Edgar Link pending
ste-20230630.xsd Edgar Link pending
ste6302023ex101.htm Edgar Link pending
ste6302023ex101001.jpg Edgar Link pending
ste6302023ex101002.jpg Edgar Link pending
ste6302023ex101003.jpg Edgar Link pending
ste6302023ex101004.jpg Edgar Link pending
ste6302023ex101005.jpg Edgar Link pending
ste6302023ex101006.jpg Edgar Link pending
ste6302023ex101007.jpg Edgar Link pending
ste6302023ex101008.jpg Edgar Link pending
ste6302023ex101009.jpg Edgar Link pending
ste6302023ex101010.jpg Edgar Link pending
ste-20230630_lab.xml Edgar Link unprocessable
ste-20230630_pre.xml Edgar Link unprocessable
ste-20230630_htm.xml Edgar Link completed
ste6302023ex101011.jpg Edgar Link pending
ste6302023ex101012.jpg Edgar Link pending
ste6302023ex101013.jpg Edgar Link pending
ste6302023ex101014.jpg Edgar Link pending
ste6302023ex101015.jpg Edgar Link pending
ste6302023ex101016.jpg Edgar Link pending
ste6302023ex101017.jpg Edgar Link pending
ste6302023ex101018.jpg Edgar Link pending
ste6302023ex101019.jpg Edgar Link pending
ste6302023ex101020.jpg Edgar Link pending
ste6302023ex101021.jpg Edgar Link pending
ste6302023ex101022.jpg Edgar Link pending
ste6302023ex101023.jpg Edgar Link pending
ste6302023ex101024.jpg Edgar Link pending
ste6302023ex101025.jpg Edgar Link pending
ste6302023ex101026.jpg Edgar Link pending
ste6302023ex101027.jpg Edgar Link pending
ste6302023ex101028.jpg Edgar Link pending
ste6302023ex101029.jpg Edgar Link pending
ste6302023ex101030.jpg Edgar Link pending
ste6302023ex101031.jpg Edgar Link pending
ste6302023ex101032.jpg Edgar Link pending
ste6302023ex101033.jpg Edgar Link pending
ste6302023ex101034.jpg Edgar Link pending
ste6302023ex101035.jpg Edgar Link pending
ste6302023ex101036.jpg Edgar Link pending
ste6302023ex101037.jpg Edgar Link pending
ste6302023ex101038.jpg Edgar Link pending
ste6302023ex101039.jpg Edgar Link pending
ste6302023ex101040.jpg Edgar Link pending
ste6302023ex101041.jpg Edgar Link pending
ste6302023ex101042.jpg Edgar Link pending
ste6302023ex101043.jpg Edgar Link pending
ste6302023ex101044.jpg Edgar Link pending
ste6302023ex101045.jpg Edgar Link pending
ste6302023ex101046.jpg Edgar Link pending
ste6302023ex101047.jpg Edgar Link pending
ste6302023ex101048.jpg Edgar Link pending
ste6302023ex101049.jpg Edgar Link pending
ste6302023ex101050.jpg Edgar Link pending
ste6302023ex101051.jpg Edgar Link pending
ste6302023ex101052.jpg Edgar Link pending
ste6302023ex101053.jpg Edgar Link pending
ste6302023ex101054.jpg Edgar Link pending
ste6302023ex101055.jpg Edgar Link pending
ste6302023ex101056.jpg Edgar Link pending
ste6302023ex101057.jpg Edgar Link pending
ste6302023ex101058.jpg Edgar Link pending
ste6302023ex101059.jpg Edgar Link pending
ste6302023ex101060.jpg Edgar Link pending
ste6302023ex101061.jpg Edgar Link pending
ste6302023ex101062.jpg Edgar Link pending
ste6302023ex101063.jpg Edgar Link pending
ste6302023ex101064.jpg Edgar Link pending
ste6302023ex101065.jpg Edgar Link pending
ste6302023ex101066.jpg Edgar Link pending
ste6302023ex101067.jpg Edgar Link pending
ste6302023ex101068.jpg Edgar Link pending
ste6302023ex101069.jpg Edgar Link pending
ste6302023ex101070.jpg Edgar Link pending
ste6302023ex101071.jpg Edgar Link pending
ste6302023ex101072.jpg Edgar Link pending
ste6302023ex101073.jpg Edgar Link pending
ste6302023ex101074.jpg Edgar Link pending
ste6302023ex101075.jpg Edgar Link pending
ste6302023ex102.htm Edgar Link pending
ste6302023ex102001.jpg Edgar Link pending
ste6302023ex102002.jpg Edgar Link pending
ste6302023ex102003.jpg Edgar Link pending
ste6302023ex102004.jpg Edgar Link pending
ste6302023ex102005.jpg Edgar Link pending
ste6302023ex102006.jpg Edgar Link pending
ste6302023ex102007.jpg Edgar Link pending
ste6302023ex102008.jpg Edgar Link pending
ste6302023ex102009.jpg Edgar Link pending
ste6302023ex102010.jpg Edgar Link pending
ste6302023ex102011.jpg Edgar Link pending
ste6302023ex102012.jpg Edgar Link pending
ste6302023ex102013.jpg Edgar Link pending
ste6302023ex102014.jpg Edgar Link pending
ste6302023ex102015.jpg Edgar Link pending
ste6302023ex102016.jpg Edgar Link pending
ste6302023ex102017.jpg Edgar Link pending
ste6302023ex102018.jpg Edgar Link pending
ste6302023ex102019.jpg Edgar Link pending
ste6302023ex102020.jpg Edgar Link pending
ste6302023ex102021.jpg Edgar Link pending
ste6302023ex102022.jpg Edgar Link pending
ste6302023ex102023.jpg Edgar Link pending
ste6302023ex102024.jpg Edgar Link pending
ste6302023ex102025.jpg Edgar Link pending
ste6302023ex102026.jpg Edgar Link pending
ste6302023ex102027.jpg Edgar Link pending
ste6302023ex102028.jpg Edgar Link pending
ste6302023ex102029.jpg Edgar Link pending
ste6302023ex102030.jpg Edgar Link pending
ste6302023ex102031.jpg Edgar Link pending
ste6302023ex102032.jpg Edgar Link pending
ste6302023ex102033.jpg Edgar Link pending
ste6302023ex102034.jpg Edgar Link pending
ste6302023ex102035.jpg Edgar Link pending
ste6302023ex102036.jpg Edgar Link pending
ste6302023ex102037.jpg Edgar Link pending
ste6302023ex102038.jpg Edgar Link pending
ste6302023ex102039.jpg Edgar Link pending
ste6302023ex102040.jpg Edgar Link pending
ste6302023ex102041.jpg Edgar Link pending
ste6302023ex102042.jpg Edgar Link pending
ste6302023ex102043.jpg Edgar Link pending
ste6302023ex102044.jpg Edgar Link pending
ste6302023ex102045.jpg Edgar Link pending
ste6302023ex102046.jpg Edgar Link pending
ste6302023ex102047.jpg Edgar Link pending
ste6302023ex102048.jpg Edgar Link pending
ste6302023ex102049.jpg Edgar Link pending
ste6302023ex102050.jpg Edgar Link pending
ste6302023ex102051.jpg Edgar Link pending
ste6302023ex102052.jpg Edgar Link pending
ste6302023ex102053.jpg Edgar Link pending
ste6302023ex102054.jpg Edgar Link pending
ste6302023ex102055.jpg Edgar Link pending
ste6302023ex102056.jpg Edgar Link pending
ste6302023ex102057.jpg Edgar Link pending
ste6302023ex102058.jpg Edgar Link pending
ste6302023ex102059.jpg Edgar Link pending
ste6302023ex102060.jpg Edgar Link pending
ste6302023ex102061.jpg Edgar Link pending
ste6302023ex102062.jpg Edgar Link pending
ste6302023ex102063.jpg Edgar Link pending
ste6302023ex102064.jpg Edgar Link pending
ste6302023ex102065.jpg Edgar Link pending
ste6302023ex102066.jpg Edgar Link pending
ste6302023ex102067.jpg Edgar Link pending
ste6302023ex102068.jpg Edgar Link pending
ste6302023ex102069.jpg Edgar Link pending
ste6302023ex102070.jpg Edgar Link pending
ste6302023ex102071.jpg Edgar Link pending
ste6302023ex103.htm Edgar Link pending
ste6302023ex103001.jpg Edgar Link pending
ste6302023ex103002.jpg Edgar Link pending
ste6302023ex103003.jpg Edgar Link pending
ste6302023ex103004.jpg Edgar Link pending
ste6302023ex103005.jpg Edgar Link pending
ste6302023ex103006.jpg Edgar Link pending
ste6302023ex103007.jpg Edgar Link pending
ste6302023ex103008.jpg Edgar Link pending
ste6302023ex103009.jpg Edgar Link pending
ste6302023ex103010.jpg Edgar Link pending
ste6302023ex103011.jpg Edgar Link pending
ste6302023ex103012.jpg Edgar Link pending
ste6302023ex103013.jpg Edgar Link pending
ste6302023ex103014.jpg Edgar Link pending
ste6302023ex103015.jpg Edgar Link pending
ste6302023ex103016.jpg Edgar Link pending
ste6302023ex103017.jpg Edgar Link pending
ste6302023ex103018.jpg Edgar Link pending
ste6302023ex103019.jpg Edgar Link pending
ste6302023ex103020.jpg Edgar Link pending
ste6302023ex103021.jpg Edgar Link pending
ste6302023ex103022.jpg Edgar Link pending
ste6302023ex103023.jpg Edgar Link pending
ste6302023ex103024.jpg Edgar Link pending
ste6302023ex103025.jpg Edgar Link pending
ste6302023ex103026.jpg Edgar Link pending
ste6302023ex103027.jpg Edgar Link pending
ste6302023ex103028.jpg Edgar Link pending
ste6302023ex103029.jpg Edgar Link pending
ste6302023ex103030.jpg Edgar Link pending
ste6302023ex103031.jpg Edgar Link pending
ste6302023ex103032.jpg Edgar Link pending
ste6302023ex103033.jpg Edgar Link pending
ste6302023ex103034.jpg Edgar Link pending
ste6302023ex103035.jpg Edgar Link pending
ste6302023ex103036.jpg Edgar Link pending
ste6302023ex103037.jpg Edgar Link pending
ste6302023ex103038.jpg Edgar Link pending
ste6302023ex103039.jpg Edgar Link pending
ste6302023ex103040.jpg Edgar Link pending
ste6302023ex103041.jpg Edgar Link pending
ste6302023ex103042.jpg Edgar Link pending
ste6302023ex103043.jpg Edgar Link pending
ste6302023ex103044.jpg Edgar Link pending
ste6302023ex103045.jpg Edgar Link pending
ste6302023ex103046.jpg Edgar Link pending
ste6302023ex103047.jpg Edgar Link pending
ste6302023ex103048.jpg Edgar Link pending
ste6302023ex103049.jpg Edgar Link pending
ste6302023ex103050.jpg Edgar Link pending
ste6302023ex103051.jpg Edgar Link pending
ste6302023ex103052.jpg Edgar Link pending
ste6302023ex103053.jpg Edgar Link pending
ste6302023ex103054.jpg Edgar Link pending
ste6302023ex103055.jpg Edgar Link pending
ste6302023ex103056.jpg Edgar Link pending
ste6302023ex103057.jpg Edgar Link pending
ste6302023ex103058.jpg Edgar Link pending
ste6302023ex103059.jpg Edgar Link pending
ste6302023ex103060.jpg Edgar Link pending
ste6302023ex103061.jpg Edgar Link pending
ste6302023ex103062.jpg Edgar Link pending
ste6302023ex103063.jpg Edgar Link pending
ste6302023ex103064.jpg Edgar Link pending
ste6302023ex103065.jpg Edgar Link pending
ste6302023ex103066.jpg Edgar Link pending
ste6302023ex103067.jpg Edgar Link pending
ste6302023ex103068.jpg Edgar Link pending
ste6302023ex103069.jpg Edgar Link pending
ste6302023ex103070.jpg Edgar Link pending
ste6302023ex103071.jpg Edgar Link pending
ste6302023ex103072.jpg Edgar Link pending
ste6302023ex103073.jpg Edgar Link pending
ste6302023ex103074.jpg Edgar Link pending
ste6302023ex103075.jpg Edgar Link pending
ste6302023ex103076.jpg Edgar Link pending
ste6302023ex103077.jpg Edgar Link pending
ste6302023ex103078.jpg Edgar Link pending
ste6302023ex103079.jpg Edgar Link pending
ste6302023ex103080.jpg Edgar Link pending
ste6302023ex103081.jpg Edgar Link pending
ste6302023ex103082.jpg Edgar Link pending
ste6302023ex103083.jpg Edgar Link pending
ste6302023ex103084.jpg Edgar Link pending
ste6302023ex103085.jpg Edgar Link pending
ste6302023ex103086.jpg Edgar Link pending
ste6302023ex103087.jpg Edgar Link pending
ste6302023ex1511.htm Edgar Link pending
ste6302023ex21.htm Edgar Link pending
ste6302023ex21001.jpg Edgar Link pending
ste6302023ex21002.jpg Edgar Link pending
ste6302023ex21003.jpg Edgar Link pending
ste6302023ex21004.jpg Edgar Link pending
ste6302023ex21005.jpg Edgar Link pending
ste6302023ex21006.jpg Edgar Link pending
ste6302023ex21007.jpg Edgar Link pending
ste6302023ex21008.jpg Edgar Link pending
ste6302023ex21009.jpg Edgar Link pending
ste6302023ex21010.jpg Edgar Link pending
ste6302023ex21011.jpg Edgar Link pending
ste6302023ex21012.jpg Edgar Link pending
ste6302023ex21013.jpg Edgar Link pending
ste6302023ex21014.jpg Edgar Link pending
ste6302023ex21015.jpg Edgar Link pending
ste6302023ex21016.jpg Edgar Link pending
ste6302023ex21017.jpg Edgar Link pending
ste6302023ex21018.jpg Edgar Link pending
ste6302023ex21019.jpg Edgar Link pending
ste6302023ex21020.jpg Edgar Link pending
ste6302023ex21021.jpg Edgar Link pending
ste6302023ex21022.jpg Edgar Link pending
ste6302023ex21023.jpg Edgar Link pending
ste6302023ex21024.jpg Edgar Link pending
ste6302023ex21025.jpg Edgar Link pending
ste6302023ex21026.jpg Edgar Link pending
ste6302023ex21027.jpg Edgar Link pending
ste6302023ex21028.jpg Edgar Link pending
ste6302023ex21029.jpg Edgar Link pending
ste6302023ex21030.jpg Edgar Link pending
ste6302023ex21031.jpg Edgar Link pending
ste6302023ex21032.jpg Edgar Link pending
ste6302023ex21033.jpg Edgar Link pending
ste6302023ex21034.jpg Edgar Link pending
ste6302023ex21035.jpg Edgar Link pending
ste6302023ex21036.jpg Edgar Link pending
ste6302023ex21037.jpg Edgar Link pending
ste6302023ex21038.jpg Edgar Link pending
ste6302023ex21039.jpg Edgar Link pending
ste6302023ex21040.jpg Edgar Link pending
ste6302023ex21041.jpg Edgar Link pending
ste6302023ex21042.jpg Edgar Link pending
ste6302023ex3111.htm Edgar Link pending
ste6302023ex3121.htm Edgar Link pending
ste6302023ex3211.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ste-20230630_cal.xml Edgar Link unprocessable
ste-20230630_def.xml Edgar Link unprocessable